Debrah, Linda Batsa
Gyasi, Charles
Ahiadorme, Monica
Rahamani, Abu Abudu
Opoku, Vera Serwaa
Obeng, Prince
Osei-Mensah, Jubin
Obeng, Michael Agyemang
Mensah, Derrick Adu
Debrah, Alexander Yaw
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (EDCTP2) programme supported by the European Union (TMA2018SF-2451-ASTAWOL, TMA2018SF-2451-ASTAWOL, TMA2018SF-2451-ASTAWOL)
Drug for Neglected Diseases initiative
Article History
Received: 3 November 2023
Accepted: 1 April 2024
First Online: 8 April 2024
Declarations
:
: Ethical approval of the study was obtained from the Committee on Human Research Publication and Ethics (CHRPE) of the School of Medicine and Dentistry of the Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana. Community leaders were consulted at the beginning of the study for their support and permission, and written approval was sought from the Western North Regional and the Sefwi Akontombra District Health Directorates. Informed consent was obtained from all participants and/or their legal guardians either by thumb printing or signing. This study was part of other larger studies titled: “The efficacy of rifampicin 35 mg/kg/d plus albendazole 400 mg/d given for 7 or 14 days against onchocerciasis– a randomized, controlled, parallel-group, open-label, phase II pilot trial” with registration number PACTR202009704006025, and “Prevalence assessment for onchocerciasis in some selected districts in Ghana”. The ethical approvals received for these studies were CHRPE/AP/359/20 and CHRPE/AP/492/20. The study was undertaken according to the principles and guidelines of the Helsinki Declaration of 1964, most recently amended in October 2013.
: Not applicable.
: The authors declare no competing interests.